RxDoctor Payments Data

Lauren Briley, MD

Gastroenterology · Louisville, KYNPI 1962537589

Payments from drug & device makers

$3,388in general payments, 2019–2025

Across 210 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$950
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$476
  • Takeda Pharmaceuticals U.S.A., Inc.$430
  • Johnson & Johnson$275
  • Intercept Pharmaceuticals, Inc.$145
  • E.r. Squibb & Sons, L.L.C.$120
  • plus $994 from 20 others

What the payments were for

  • Consulting fees$110%
  • Food & beverage$3,34299%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,388 in reported general payments places this provider in the 45th percentile of 207 gastroenterology providers in Kentucky.

See all gastroenterology providers in Kentucky

Medicare billing

Part B allowed, 2024
$148,905
Medicare patients
671
Services billed
1,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab41$1,150,388
Humira(Cf) PenAdalimumab19$197,539
XifaxanRifaximin13$40,885
LinzessLinaclotide40$33,937
CreonLipase/Protease/Amylase15$25,069
Mesalamine17$13,041
Mesalamine ErMesalamine20$11,562
Colestipol Hcl58$6,008
Dexlansoprazole DrDexlansoprazole19$4,588
Pantoprazole Sodium332$4,216
Budesonide DrBudesonide27$3,580
Lubiprostone26$3,179
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine77$2,784
Azathioprine16$2,227
Omeprazole228$2,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$275$1,150,38841 claims
AbbVieLinzess, Creon$950$59,00555 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$476$40,88513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 207 gastroenterology providers in Kentucky.

Other gastroenterology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →